Syros Pharmaceuticals (SYRS) Expected to Post Quarterly Sales of $1.33 Million

Equities analysts predict that Syros Pharmaceuticals (NASDAQ:SYRS) will announce sales of $1.33 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from $370,000.00 to $3.21 million. The company is expected to issue its next earnings report on Wednesday, August 8th.

On average, analysts expect that Syros Pharmaceuticals will report full-year sales of $3.34 million for the current financial year, with estimates ranging from $370,000.00 to $10.00 million. For the next financial year, analysts expect that the business will report sales of $1.53 million per share, with estimates ranging from $600,000.00 to $2.50 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.14). The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $3.41 million.

Several equities analysts have recently commented on SYRS shares. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 22nd. Zacks Investment Research lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. Wedbush reaffirmed an “outperform” rating and set a $13.00 price objective (up previously from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, Cann reaffirmed a “buy” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, May 10th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $21.13.

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in Syros Pharmaceuticals in the fourth quarter worth about $191,000. ARK Investment Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 519.7% during the fourth quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock worth $8,122,000 after purchasing an additional 700,058 shares during the period. Candriam Luxembourg S.C.A. lifted its holdings in shares of Syros Pharmaceuticals by 75.0% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 210,000 shares of the company’s stock worth $2,043,000 after purchasing an additional 90,000 shares during the period. Two Sigma Advisers LP acquired a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth about $105,000. Finally, Adalta Capital Management LLC acquired a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth about $111,000. 56.84% of the stock is owned by institutional investors and hedge funds.

Shares of Syros Pharmaceuticals stock traded down $0.30 during trading on Friday, hitting $12.78. 2,023 shares of the stock traded hands, compared to its average volume of 245,097. The firm has a market cap of $435.57 million, a P/E ratio of -6.14 and a beta of -2.69. Syros Pharmaceuticals has a 52-week low of $6.30 and a 52-week high of $24.38.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply